Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.
|Translated title of the contribution||Advances in staging and therapy of multiple myeloma|
|Number of pages||7|
|Journal||Recenti Progressi in Medicina|
|Publication status||Published - 1994|
ASJC Scopus subject areas